SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Half Yearly Report

10 Dec 2013 07:00

RNS Number : 1046V
Healthcare Investment Opportunities
10 December 2013
 



Healthcare Investment Opportunities plc

 

Unaudited Statement of Comprehensive Income

for the six months to 30 September 2013

 

Healthcare Investment Opportunities plc (AIM: HIO), an investment company focusing on the healthcare sector, is pleased to announce its inaugural set of unaudited interim results for the six month period ended 30 September 2013. These have been posted to shareholders today and are available on the Company's website at www.healthcareinvestmentopps.co.uk.

 

Commenting on the results, David Evans, Chairman of Healthcare Investment Opportunities plc said:

 

"Since HIO listed on AIM in April 2013, both the board and myself have been actively reviewing acquisition opportunities, and have looked at over 30 opportunities in this time. We are delighted that the proposed acquisition of Collbio Limited was announced earlier this morning and are confident that the acquisition will be value enhancing for shareholders if the transaction is approved at the general meeting scheduled for 27 December 2013."

 

Enquiries:

 

Healthcare Investment Opportunities Plc

David Evans, Chairman

 

Tel: 07740 084 452

Zeus Capital (Nominated Adviser and Broker)

Corporate Finance

Ross Andrews

John Depasquale

Tel: 0161 831 1512

 

Institutional Sales

John Goold

Dominic Wilson

 

 

Tel: 020 7533 7727

Tel: 020 7533 7721

Walbrook PR Ltd

Tel: 020 7933 8780 or hio@walbrookpr.com

Paul McManus 

Mike Wort

Mob: 07980 541 893

 

 

 

Unaudited Statement of Comprehensive Income

6 months to 30 September 2013

£

Continuing operations

Administrative expenses

(62,631)

OPERATING LOSS

(62,631)

Interest receivable and similar income

-

LOSS BEFORE TAXATION

(62,631)

Tax on loss on ordinary activities

-

LOSS FOR THE PERIOD

(62,631)

 

Other comprehensive income, net of tax

-

TOTAL COMPREHENSIVE LOSS FOR THE PERIOD ATTRIBUTABLE TO OWNERS OF THE PARENT

(62,631)

 

LOSS PER ORDINARY SHARE (PENCE)

Basic

(Note 2)

(0.15)p

Diluted

(Note 2)

(0.15)p

 

 

Unaudited Statement of Changes in Equity

 for the six month period to 30th September, 2013

 

 

Share

Share

premium

Retained

Total

capital

account

earnings

Equity

£

£

£

£

(Loss) for the six month period

-

-

(62,631)

(62,631)

Funds raised

405,000

3,645,000

-

4,050,000

Issue expenses

-

(360,060)

-

(360,060)

At 30th September, 2013

405,000

3,284,940

(62,631)

3,627,309

 

 

Unaudited Statement of Financial Position

as at 30th September 2013

 

 

£

As at 30 September 2013

ASSETS

Current assets

Cash and cash equivalents

3,632,309

3,632,309

TOTAL ASSETS

3,632,309

LIABILITIES

Current liabilities

Trade and other payables

5,000

NET CURRENT ASSETS

3,627,309

NET ASSETS

3,627,309

TOTAL EQUITY

Called up share capital

405,000

Share premium account

3,284,940

Retained earnings

(62,631)

3,627,309

 

 

 

Unaudited Cash Flow Statement

for the six month period to

30th September 2013

 

 

6 months

30 September 2013

£

Cash flows from operating activities

Operating (loss) for the period

(62,631)

Increase in trade and other payables

5,000

Cash generated from operations

(57,631)

Income taxes received

-

Net cash used in operating activities

(57,631)

Cash flows from financing activities

Proceeds from issue of share capital

4,050,000

Expenses of share issue

(360,060)

Net cash generated from financing activities

3,689,940

Net increase in cash and cash equivalents

3,632,309

Cash and cash equivalents at end of the period

3,632,309

 

 

 

 

Notes to the Interim Financial Statements

for the period to 30th September, 2013

 

1 Basis of preparation

 

The interim financial statements have been prepared in accordance with the AIM rules and on the basis of all International Financial Reporting Standards ("IFRS") as adopted by the European Union that are expected to be applicable to the Company's statutory accounts for the year ended 31st March 2014. The interim financial statements are unaudited and were approved by the Directors on 9 December 2013. The information set out herein is abbreviated and does not constitute statutory accounts within the meaning of Section 434 of the Companies Act 2006.

 

The Company has not applied IAS 34, Interim Financial Reporting, which is not mandatory for UK Groups, in the preparation of these interim financial statements.

 

The Company is a limited liability company incorporated and domiciled in England & Wales and whose shares are quoted on AIM, a market operated by The London Stock Exchange. The financial information of Healthcare Investment Opportunities plc is presented in Pounds Sterling (£), which is also the functional currency of the Company.

 

 

2 Loss per share

 

Basic loss per share, from continuing operations, is calculated by dividing the earnings attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the year.

 

The calculations of earnings per share are based on the following losses and numbers of shares.

 

6 months to

30 September 2013

 

Loss after taxation (62,631)

 

Weighted average number of shares 40,500,000

 

Basic earnings per share (0.15)p

 

At 30th September, 2013 the Company had 40,500,000 Ordinary Shares of 1p in issue.

 

The loss for the period and the weighted average number of ordinary shares for calculating the diluted earnings per share for the six months ended 30 September 2013 are identical to those used for the basic earnings per share.

 

3 Interim results

 These results were approved by the Board of Directors on 9 December 2013.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR DDBDDCDGBGXC
Date   Source Headline
30th Aug 201711:21 amRNSResult of AGM
30th Aug 20177:00 amRNSAGM Statement
26th Jul 20177:00 amRNSPosting of Annual Report & notice of AGM
25th Jul 201711:36 amRNSDirector/PDMR Shareholding
25th Jul 20177:15 amRNSHardman Research: Transition to sustainable growth
13th Jul 201711:39 amRNSDirector/PDMR Shareholding
11th Jul 20177:00 amRNSFinal Results
7th Jul 20177:00 amRNSFirst patient enrolment in ChondroMimetic® study
19th Jun 20177:00 amRNSNotice of Results
13th Jun 20177:00 amRNSProvisional patent submitted
11th May 20177:15 amRNSHardman Research: Trading:earnings above forecasts
25th Apr 20177:00 amRNSTrading Update
24th Apr 20177:00 amRNSConsolidation of US R&D activities & Board change
10th Apr 20177:00 amRNSCollagen Based Spray Adhesive Poster Presented
3rd Apr 201711:22 amRNSHolding(s) in Company
3rd Apr 20177:00 amRNSAgreement signed with Smart Matrix Limited
31st Mar 20174:52 pmRNSHolding(s) in Company
29th Mar 20177:00 amRNSPericardium Divisional Patent in Australia
27th Mar 201712:39 pmRNSDirector/PDMR Shareholding
24th Mar 20179:26 amRNSDirector/PDMR Shareholding
23rd Mar 20177:00 amRNSAttending UK Investor Show
20th Mar 20178:56 amRNSIntroduces new online sales initiative in the US
15th Mar 20179:58 amRNSHolding(s) in Company
14th Mar 20173:28 pmRNSHolding(s) in Company
13th Mar 201711:52 amRNSHardman Research: Engineering cartilage repairs
13th Mar 20179:57 amRNSHolding(s) in Company
13th Mar 20177:05 amRNSHardman Research: Engineering cartilage repairs
9th Mar 20177:00 amRNSHolding(s) in Company
9th Mar 20177:00 amRNSHolding(s) in Company
9th Mar 20177:00 amRNSAttending AAOS and ORS meetings in San Diego
8th Mar 20177:00 amRNSDirector/PDMR Shareholding
7th Mar 20174:08 pmRNSHolding(s) in Company
7th Mar 20171:01 pmRNSDirector/PDMR Shareholding
7th Mar 201711:19 amRNSHolding(s) in Company
7th Mar 20179:56 amRNSHolding(s) in Company
6th Mar 20172:24 pmRNSResult of General Meeting
20th Feb 20177:00 amRNSInvestor presentation
15th Feb 201711:29 amRNSGrant of Options
14th Feb 201711:24 amRNSHardman Research: Funding accelerated growth
14th Feb 20177:00 amRNSPlacing Open Offer and Debt Financing
7th Feb 20177:00 amRNSAttends MD&M West Conference in Anaheim
19th Jan 20177:00 amRNSNew Scientific Advisory Board appointments
13th Jan 20177:00 amRNSThird Medical Research Scotland Ph.D. Studentship
21st Dec 201612:06 pmRNSHardman Research: Foundations for strategic growth
19th Dec 20167:00 amRNSHalf-year Report
14th Dec 20167:00 amRNSPoster Presentation at TERMIS-AM
2nd Dec 20167:00 amRNSNotice of Results
13th Oct 20167:00 amRNSTrading Statement
3rd Oct 20167:00 amRNSChange of Adviser
15th Sep 20167:00 amRNSParticipation in major Horizon 2020 project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.